Clozapine withdrawal-emergent dystonias and dyskinesias: a case series
- PMID: 9771818
- DOI: 10.4088/jcp.v59n0906
Clozapine withdrawal-emergent dystonias and dyskinesias: a case series
Abstract
Background: Severe psychotic decompensation during clozapine withdrawal has been reported previously. Less attention has been paid to movement disorders following abrupt clozapine withdrawal. This report describes 4 subjects who experienced severe dystonias and dyskinesias upon abrupt clozapine withdrawal.
Method: Current and past medical records of 4 subjects with DSM-IV schizophrenia or schizo-affective disorder were reviewed.
Results: All subjects had a history of neuroleptic-induced extrapyramidal symptoms, 1 had a history of severe dystonias, and 1 had neuroleptic malignant syndrome. All had mild orolingual tardive dyskinesia prior to clozapine treatment. All subjects had received clozapine for several months, and 3 of the 4 subjects stopped clozapine abruptly. Two subjects experienced cholinergic rebound symptoms within hours, which resolved quickly. These subjects had severe limb-axial and neck dystonias and dyskinesias 5 to 14 days after clozapine withdrawal. Two subjects were unable to ambulate, and 1 had a lurching gait. Two gagged while eating or drinking. Two subjects were returned to clozapine, 1 was started on low-dose risperidone treatment, and 1 was started on olanzapine treatment. All experienced significant improvements in their mental state and movement disorders.
Conclusion: Severe movement disorders, which may be worse than the movements prior to clozapine treatment, and cholinergic rebound symptoms may occur upon abrupt clozapine withdrawal and must be recognized in addition to the severe psychotic decompensation noted in some patients. Patients, families, and caregivers must be alerted to this possibility. Where possible, a slow clozapine taper, the use of anticholinergic agents, and symptomatic treatment may help minimize these withdrawal symptoms, and reintroduction of clozapine or treatment with the newer atypical agents can help in the clinical management of these symptoms.
Similar articles
-
Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal.Schizophr Bull. 1996;22(4):591-5. doi: 10.1093/schbul/22.4.591. Schizophr Bull. 1996. PMID: 8938913 Clinical Trial.
-
Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes: A Naturalistic Observational Study in Patients With Psychotic Disorders.J Clin Psychopharmacol. 2019 Nov/Dec;39(6):591-596. doi: 10.1097/JCP.0000000000001114. J Clin Psychopharmacol. 2019. PMID: 31688397
-
Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases.Mov Disord. 1994 May;9(3):321-4. doi: 10.1002/mds.870090308. Mov Disord. 1994. PMID: 7913739
-
The treatment of tardive dyskinesia and tardive dystonia.J Clin Psychiatry. 2000;61 Suppl 4:39-44. J Clin Psychiatry. 2000. PMID: 10739330 Review.
-
The treatment of tardive dyskinesia.Schweiz Arch Neurol Psychiatr (1985). 1996;147(1):13-8. Schweiz Arch Neurol Psychiatr (1985). 1996. PMID: 8685689 Review.
Cited by
-
Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.Drug Saf. 2005;28(3):191-208. doi: 10.2165/00002018-200528030-00002. Drug Saf. 2005. PMID: 15733025 Review.
-
Switching between second-generation antipsychotics: why and how?CNS Drugs. 2005;19(1):27-42. doi: 10.2165/00023210-200519010-00003. CNS Drugs. 2005. PMID: 15651903 Review.
-
Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis.Front Psychiatry. 2020 Sep 29;11:569912. doi: 10.3389/fpsyt.2020.569912. eCollection 2020. Front Psychiatry. 2020. PMID: 33132934 Free PMC article.
-
Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.Curr Neuropharmacol. 2009 Dec;7(4):315-30. doi: 10.2174/157015909790031184. Curr Neuropharmacol. 2009. PMID: 20514211 Free PMC article.
-
COVID-19 infection, fluctuations in the clozapine/norclozapine levels and metabolic ratio and clozapine toxicity: An illustrative case-report.Schizophr Res. 2022 Jun;244:66-68. doi: 10.1016/j.schres.2022.05.009. Epub 2022 May 19. Schizophr Res. 2022. PMID: 35605549 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous